Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 4—April 2019
Synopsis

Mucosal Leishmaniasis in Travelers with Leishmania braziliensis Complex Returning to Israel

Michal Solomon, Nadav Sahar, Felix Pavlotzky, Aviv Barzilai, Charles L. Jaffe, Abedelmajeed Nasereddin, and Eli SchwartzComments to Author 
Author affiliations: Sheba Medical Center, Tel Aviv, Israel (M. Solomon, N. Sahar, F. Pavlotzky, A. Barzilai, E. Schwartz); Hebrew University–Hadassah Medical School, Jerusalem, Israel (C.L. Jaffe, A. Nasereddin)

Main Article

Table 2

Epidemiologic, clinical, and therapy data of patients with mucosal leishmaniasis, Israel, 1993–2015*

Patient no.
Age, y/ sex
No. primary lesions
Concurrent active CL
Location of primary lesions
Treatment
ML symptoms
Primary cutaneous lesions
Mucosal lesions
After ML treatment failure
Response
1
28/M
12
No
Trunk, upper extremities
None
IV SSG
No failure
CR
Oral ulceration, nasal obstruction
2
24/F
1
Yes
Lower extremities
Treated for concurrent CL
IV SSG
No failure
CR
Nasal obstruction
3
28/M
1
No
Lower extremities
None
IV L-AmB
No failure
CR
Nasal obstruction
4
28/M
1
No
Neck
IV SSG
IV L-AmB
No failure
CR
Nasal obstruction
5
26/M
1
No
Lower extremities
IV SSG
IV L-AmB
No failure
CR
Nasal obstruction
6
25/M
1
No
Face
IV SSG
IV L-AmB
No failure
CR
Oral ulceration
7
41/M
1
Yes
Lower extremities
Treated for concurrent CL
IV L-AmB
IV SSG
CL recurrence
Nasal obstruction, lacrimal gland obstruction
8
23/M
4
Yes
Neck, lower extremities
Treated for concurrent CL
IV L-AmB
No failure
None
Nasal obstruction, bone lesion
9
31/M
3
No
Upper and lower extremities
None
IV L-AmB
No failure
CR
Nasal obstruction, rhinorrhea
10
24/M
1
Yes
Upper extremities
Treated for concurrent CL
IV L-AmB
Miltefosine
CR
Nasal obstruction
11
41/M
0
No
No lesions†
None
Miltefosine
No failure
CR
Oral ulceration
12
25/M
1
NA
NA
None
IV SSG
No failure
CR
NA
13
22/M
2
No
NA
None
IV SSG
No failure
CR
Oral ulceration
14
25/M
3
No
Lower extremities
None
IV SSG
No failure
CR
NA
15
24/M
7
No
Face, upper extremities
None
IV SSG
No failure
CR
Oral ulceration, nasal obstruction
16
28/M
1
No
Upper extremities
None
IV L-AmB
No failure
CR
Nasal obstruction
17 23/M 2 No Trunk None IV L-AmB Miltefosine CR Nasal obstruction

*CL, cutaneous leishmaniasis; CR, complete response; IV L-AmB, intravenous liposomal amphotericin B; IV SSG, intravenous sodium stibogluconate; ML, mucosal leishmaniasis; NA, not available.
†Patient 11 had no primary cutaneous lesion.

Main Article

Page created: March 17, 2019
Page updated: March 17, 2019
Page reviewed: March 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external